0000899243-20-009605.txt : 20200326 0000899243-20-009605.hdr.sgml : 20200326 20200326210029 ACCESSION NUMBER: 0000899243-20-009605 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200324 FILED AS OF DATE: 20200326 DATE AS OF CHANGE: 20200326 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bazemore Robert B CENTRAL INDEX KEY: 0001620152 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35945 FILM NUMBER: 20747671 MAIL ADDRESS: STREET 1: 33 HAYDEN AVE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Epizyme, Inc. CENTRAL INDEX KEY: 0001571498 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261349956 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-229-5872 MAIL ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-24 0 0001571498 Epizyme, Inc. EPZM 0001620152 Bazemore Robert B C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 1 0 0 President & CEO Common Stock, par value $0.0001 2020-03-24 4 J 0 56537 0.00 D 80726 D Common Stock, par value $0.0001 2020-03-24 4 A 0 113393 0.00 A 250656 D Common Stock, par value $0.0001 2020-03-24 4 A 0 7000 0.00 A 257656 D Common Stock, par value $0.0001 2020-03-25 4 S 0 3285 15.28 D 254371 D Stock Option (Right to Buy) 8.98 2020-03-24 4 J 0 79167 0.00 D 2026-02-07 Common Stock 79167 333333 D Stock Option (Right to Buy) 12.45 2020-03-24 4 J 0 2371 0.00 D 2027-02-07 Common Stock 2371 333333 D Stock Option (Right to Buy) 9.12 2020-03-24 4 J 0 48727 0.00 D 2029-01-23 Common Stock 48727 298737 D Stock Option (Right to Buy) 16.14 2020-03-24 4 A 0 73409 0.00 A 2030-03-23 Common Stock 73409 73409 D Represents the portion of stock options and restricted stock units granted to Mr. Bazemore that inadvertently were granted in excess of the annual per participant limit under the Company's 2013 Stock Incentive Plan and have been rescinded. The Company has granted to Mr. Bazemore the referenced stock options (see footnote 8) and restricted stock units (see footnote 2) to replace the fair value of the rescinded stock options and restricted stock units and provide Mr. Bazemore with the equity incentive compensation that Mr. Bazemore was intended to receive with the rescinded grants. Consists of shares of common stock issuable under restricted stock units granted pursuant to the Company's 2013 Stock Incentive Plan. Each restricted stock unit represents the right to receive one share of common stock upon vesting. 56,537 of the restricted stock units are scheduled to vest in three equal annual installments on January 24, 2021, January 24, 2022 and January 24, 2023. The balance of the restricted stock units are scheduled to vest in two equal annual installments over two years from the grant date. Represents common stock issued upon vesting of restricted stock units granted under the issuer's 2013 Stock Incentive Plan that vested upon the issuer's achievement of a specified performance target. The transaction date represents the date on which the issuer's Compensation Committee determined that the performance target was achieved. Represents shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the restricted stock units described in footnote 6. The automatic sale of the reporting person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person. The remaining stock options, which were originally granted to Mr. Bazemore on February 8, 2016, have vested in full. The remaining stock options, which were originally granted to Mr. Bazemore on February 8, 2017, are vested with respect to 258,771 shares, with (i) 69,939 of the remaining unvested shares vesting in ten substantially equal monthly installments from April 8, 2020 through January 8, 2021 and (ii) 4,623 of the remaining shares vesting on February 8, 2021. The remaining stock options, which were originally granted to Mr. Bazemore on January 24, 2019, are vested with respect to 101,343 shares, with (i) 188,210 of the remaining unvested shares vesting in 26 substantially equal monthly installments from April 24, 2020 through May 24, 2022 (ii) 1,945 of the remaining unvested shares vesting on June 24, 2022 and (iii) 7,239 of the remaining unvested shares vesting on January 24, 2023. This stock option was granted on March 24, 2020 under the Company's 2013 Stock Incentive Plan and (i) is vested in full with respect to 44,047 shares, (ii) vests in full on February 8, 2021 with respect to 1,829 shares and (iii) with respect to the remaining 27,533 shares of common stock, vests in seven substantially equal monthly installments, with the first installment vesting on June 24, 2022 and the last installment vesting on December 24, 2022. /s/ John Weidenbruch, attorney-in-fact 2020-03-26